Clinical Trial Update: Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial assessing the combination of interferon alfa and imatinib mesylate in patients with chronic myeloid leukemia has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib mesylate (Imatinib)
• Interferon Alfa (interferon alfa)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Leukemia | Phase 2 | Status: COMPLETED